|
Colitis
|
0.010 |
Biomarker
|
disease |
BEFREE |
To achieve so, we used our recently developed mouse model, in which colon cancer arises in the absence of urokinase-type plasminogen activator (uPA) due to colitis induced by dextran sodium sulfate (DSS) treatment.
|
31758376 |
2020 |
|
Heart failure
|
0.010 |
Biomarker
|
disease |
BEFREE |
Soluble urokinase-type plasminogen activator receptor represents exercise tolerance and predicts adverse cardiac events in patients with heart failure.
|
31741050 |
2019 |
|
Hyperinsulinism
|
0.010 |
Biomarker
|
disease |
BEFREE |
LA administration did not affect strain differences under RD but attenuated αMUPA's hyperinsulinemia and DIO under HFD, most likely by mediating energy expenditure.
|
31454257 |
2019 |
|
Hypertensive disease
|
0.010 |
Biomarker
|
group |
BEFREE |
Background Increased blood pressure ( BP ) variability and nondipping status seen on 24-hour ambulatory BP monitoring are often observed in autonomic failure ( ATF ).
|
30905258 |
2019 |
|
Nasal Polyps
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Primary human nasal epithelial cells (HNEC) were isolated from CRSsNP patient and treated with uPA knockdown/overexpression lentivirus.
|
30605632 |
2019 |
|
Obesity
|
0.010 |
Biomarker
|
disease |
BEFREE |
This study therefore supports the use of αMUPA mice for elucidating developmental mechanisms of obesity and the efficacy of early-life manipulations via leptin surge axis in attenuating DIO.
|
31454257 |
2019 |
|
Retinitis Pigmentosa
|
0.010 |
Biomarker
|
disease |
BEFREE |
The urokinase-type plasminogen activator (uPA) system contributes to retinal inflammation, but its role in RP is unknown.
|
31251468 |
2019 |
|
Pure Autonomic Failure
|
0.010 |
Biomarker
|
disease |
BEFREE |
Background Increased blood pressure ( BP ) variability and nondipping status seen on 24-hour ambulatory BP monitoring are often observed in autonomic failure ( ATF ).
|
30905258 |
2019 |
|
Sentinel node (disorder)
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
We focused on sentinel lymph node (SLN)-targeted therapy using the urokinase-type plasminogen activator (uPA)-dependent oncolytic Sendai virus "BioKnife."
|
31171582 |
2019 |
|
cardiac event
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
Soluble urokinase-type plasminogen activator receptor represents exercise tolerance and predicts adverse cardiac events in patients with heart failure.
|
31741050 |
2019 |
|
Endothelial dysfunction
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
Fibrinolytic regulators, such as plasminogen (Plg), plasmin, α2-antiplasmin (α2AP), tissue-type plasminogen activator (tPA), urokinase-type plasminogen activator (uPA) and its receptor (uPAR), plasminogen activator inhibitor 1 (PAI-1), and angiostatin, are considered to play an important role in the maintenance of endothelial homeostasis, and are associated with the endothelial dysfunction of SSc.
|
30709025 |
2019 |
|
Influenza A
|
0.010 |
Biomarker
|
disease |
BEFREE |
High titer MVA and influenza A virus production using a hybrid fed-batch/perfusion strategy with an ATF system.
|
30796494 |
2019 |
|
Allergic rhinitis (disorder)
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Immunohistochemical staining revealed that most of the fibrinolysis system and coagulation cascade components were localized to the epithelium, endothelium, and submucosal glands of the nasal mucosa. u-PA was downregulated in the AR group, whereas fibrin deposition was more prominent in the AR group than in the control group.
|
30518218 |
2019 |
|
HER2-negative breast cancer
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Our study indicates that uPA and PAI-1 tumor tissue levels and 4G/5G variants of PAI-1 gene might be of prognostic significance in early node-negative luminal HER2-negative breast cancer patients treated with adjuvant endocrine therapy.
|
30646864 |
2019 |
|
Non-metastatic prostate cancer
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Expression of urokinase-type plasminogen activator system in non-metastatic prostate cancer.
|
31797075 |
2019 |
|
Arthritis
|
0.010 |
Biomarker
|
disease |
BEFREE |
Our aim was to test the potential in mice of an Ab that blocks the proteolytic capacity of uPA in the CIA model and the delayed-type hypersensitivity arthritis model.
|
29282305 |
2018 |
|
Kidney Diseases
|
0.010 |
Biomarker
|
group |
BEFREE |
What is the Role of Soluble Urokinase-Type Plasminogen Activator in Renal Disease?
|
29909410 |
2018 |
|
Periodontitis
|
0.010 |
Biomarker
|
disease |
BEFREE |
Soluble urokinase-type plasminogen activator receptor is associated with signs of periodontitis in adolescents.
|
29752756 |
2018 |
|
Rheumatism
|
0.010 |
Biomarker
|
disease |
BEFREE |
The data from animal models and human material provide preclinical proof-of-principle that validates uPA as a novel therapeutic target in rheumatic diseases.
|
29282305 |
2018 |
|
Stress, Psychological
|
0.010 |
Biomarker
|
disease |
BEFREE |
As different types of PA may have different determinants, the effects of LS on participation in moderate-to-vigorous PA (MVPA) and on organized and unorganized PA (OPA, UPA) were examined in a sample of 937 students (10-11 years-old) followed up over five years.
|
30170013 |
2018 |
|
Esophageal carcinoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Kaplan-Meier analysis showed that the overall survival time of patients with positive expression of uPA or p38MAPK protein was significantly shorter, and the time of recurrence or metastasis of esophageal cancer was significantly earlier in patients with uPA-positive expression.
|
30568465 |
2018 |
|
Malignant neoplasm of esophagus
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Kaplan-Meier analysis showed that the overall survival time of patients with positive expression of uPA or p38MAPK protein was significantly shorter, and the time of recurrence or metastasis of esophageal cancer was significantly earlier in patients with uPA-positive expression.
|
30568465 |
2018 |
|
Communicating Hydrocephalus
|
0.010 |
Biomarker
|
disease |
BEFREE |
In the present study, we tested the hypothesis that urokinase (also known as urokinase-type plasminogen activator [uPA]), a fibrinolytic agent, attenuates fibrosis and ventriculomegaly in a rat model of kaolin-induced communicating hydrocephalus and thus may have potential as a therapy for these conditions.
|
27614013 |
2017 |
|
Diabetic Retinopathy
|
0.010 |
Biomarker
|
disease |
BEFREE |
The system formed by urokinase-type plasminogen activator (uPA) and its receptor (uPAR) is a player in blood-retinal barrier (BRB) breakdown in DR.
|
29464181 |
2017 |
|
Epilepsy
|
0.010 |
Biomarker
|
disease |
BEFREE |
Strong association of reduced [<sup>111</sup> In]MICA-401 binding with seizure burden in the KASE model suggests that analysis of reduced levels of active uPA/KLK8 represents a novel biomarker candidate to be explored as a biomarker for epilepsy severity.
|
28722103 |
2017 |